NU505 Unit 2 Assignment: Aortic Abdominal Aneurysm

NU505 Unit 2 Assignment: Aortic Abdominal Aneurysm

Student Name

Purdue University Global

NU505 Clinical Epidemiology and Population Health Promotion

Prof. Name:

Date

Abdominal Aortic Aneurysm (AAA): Causes, Risk Factors, Epidemiology, and Screening

An abdominal aortic aneurysm (AAA) is an enlargement of the abdominal portion of the aorta that occurs when the artery wall weakens and expands beyond its normal size. Most AAAs develop without symptoms, making early detection through ultrasound screening essential, especially for men aged 65–75 years who have a history of smoking. Timely diagnosis significantly reduces the risk of rupture, a life-threatening emergency associated with severe internal bleeding. Understanding the causes, risk factors, and screening recommendations can improve early intervention and patient outcomes.

Understanding Abdominal Aortic Aneurysm

An abdominal aortic aneurysm (AAA) develops when a section of the abdominal aorta gradually enlarges due to weakening of the arterial wall. The aorta is the body’s largest artery and carries oxygen-rich blood from the heart to the abdomen, pelvis, and lower limbs. As the aneurysm grows, the vessel wall becomes increasingly fragile, raising the likelihood of rupture.

Most AAAs remain asymptomatic during the early stages and are often discovered incidentally during imaging performed for unrelated medical conditions. However, once an aneurysm ruptures, it becomes a medical emergency requiring immediate surgical intervention because of the high risk of fatal internal hemorrhage.

The exact cause of AAA remains unclear, but research suggests that chronic inflammation, degeneration of the arterial wall, genetic predisposition, and cardiovascular risk factors all contribute to its development.

Major Risk Factors for Abdominal Aortic Aneurysm

Several well-established factors increase an individual’s likelihood of developing an AAA. While some risks are modifiable, others are related to genetics or age.

Key risk factors include:

• Smoking (the strongest modifiable risk factor)

• Age over 65 years

• Male sex

• Hypertension (high blood pressure)

• Hyperlipidemia

• Family history of AAA

• Atherosclerosis

• Obesity

• Certain inherited genetic variants

Recent genome-wide association studies have identified several genetic loci associated with increased susceptibility to AAA, including:

• CDKN2B-AS1

• DAB2IP

• LRP1

• LDLR

• SORT1

These genetic discoveries are improving researchers’ understanding of aneurysm formation and may contribute to future personalized screening and treatment strategies (Roychowdhury et al., 2023).

Why Smoking Significantly Increases AAA Risk

Smoking is considered the most influential modifiable risk factor for abdominal aortic aneurysm. Long-term tobacco exposure damages blood vessel walls, accelerates atherosclerosis, and promotes inflammation, all of which weaken the aortic wall.

Current and former smokers are substantially more likely to develop AAA than individuals who have never smoked. Additionally, smokers tend to develop aneurysms at younger ages and experience faster aneurysm growth.

Smoking cessation remains one of the most effective preventive measures for reducing AAA-related morbidity and mortality.

Epidemiology of Abdominal Aortic Aneurysm

Abdominal aortic aneurysm primarily affects older adults, particularly men. Although improvements in smoking cessation and cardiovascular disease management have reduced AAA prevalence over recent decades, it remains a significant cause of preventable death.

Between 2018 and 2021, abdominal aortic aneurysm accounted for approximately 13,640 deaths in the United States, with an overall mortality rate of roughly 1 death per 100,000 people. Men represented the majority of affected individuals, reflecting the strong association between male sex and aneurysm development.

Age plays a major role in disease prevalence. Population-based research has shown that among men:

• Ages 65–74 years: approximately 55 cases per 100,000

• Ages 75–85 years: approximately 112 cases per 100,000

• Older than 85 years: approximately 298 cases per 100,000

These findings demonstrate that the risk of AAA rises substantially with advancing age.

Prevalence of AAA in High-Risk Populations

A large U.S. ultrasound screening study involving 9,457 participants provided additional insight into populations at greatest risk.

The study reported:

• Average participant age: 67 years

• Men represented 47% of participants.

• Most participants were between 65 and 75 years of age.

• Common cardiovascular risk factors included:

  • Hypertension

  • Hyperlipidemia

  • Smoking

  • Cardiac disease

  • Diabetes mellitus

  • Family history of AAA

  • Elevated body mass index

Overall, 2.82% of participants were diagnosed with an abdominal aortic aneurysm measuring greater than 3 cm, while the prevalence among men aged 65–75 years reached nearly 3% (Summers et al., 2019).

These findings suggest that screening recommendations may benefit additional high-risk populations, particularly younger male smokers with multiple cardiovascular risk factors.

Current Screening Recommendations

Because most AAAs remain asymptomatic until they enlarge or rupture, screening plays a vital role in reducing mortality.

The U.S. Preventive Services Task Force (USPSTF) recommends:

• A one-time abdominal ultrasound for men aged 65–75 years who have ever smoked.

• Selective screening for men aged 65–75 years who have never smoked, based on individual risk factors such as family history and cardiovascular disease.

• Routine screening is not currently recommended for women who have never smoked and have no family history of AAA because of the low prevalence and limited evidence of benefit.

Ultrasonography remains the preferred screening method because it is:

• Non-invasive

• Highly accurate

• Inexpensive

• Free of radiation exposure

• Widely available

Early identification allows clinicians to monitor aneurysm growth and determine the most appropriate timing for intervention before rupture occurs.

Evidence-Based Clinical Insight

Multiple population-based studies consistently demonstrate that targeted ultrasound screening significantly reduces deaths caused by ruptured abdominal aortic aneurysms. Screening is most beneficial for older men with a history of smoking because this group carries the highest lifetime risk of aneurysm formation and rupture. Continued research is evaluating whether additional high-risk populations may also benefit from earlier or expanded screening strategies.

How Is an Abdominal Aortic Aneurysm Diagnosed?

Early diagnosis is critical because most abdominal aortic aneurysms (AAAs) do not cause symptoms until they become large or rupture. Healthcare providers often discover AAAs during routine imaging performed for other medical conditions. However, targeted screening of high-risk individuals remains the most effective strategy for early detection.

Ultrasonography is considered the gold standard for screening and diagnosing AAA because it is safe, non-invasive, cost-effective, and highly accurate. According to evidence reviewed by the U.S. Preventive Services Task Force (USPSTF), abdominal ultrasound has:

• Sensitivity: 94%–100%

• Specificity: 98%–100%

These high levels of accuracy make ultrasound the preferred first-line imaging technique for identifying aneurysms and monitoring their growth over time.

Why Ultrasound Is the Preferred Screening Method

Abdominal ultrasonography offers several advantages over other imaging techniques.

Key benefits include:

• No exposure to ionizing radiation

• Quick and painless procedure

• High diagnostic accuracy

• Relatively low cost

• Suitable for routine population screening

• Effective for monitoring aneurysm progression

Although computed tomography (CT) angiography provides more detailed anatomical information, it is generally reserved for surgical planning, emergency evaluation, or complex cases rather than routine screening.

Evidence from Major AAA Screening Trials

The recommendation for one-time ultrasound screening is supported by several large randomized controlled trials conducted in Australia, Denmark, and the United Kingdom. These studies evaluated whether screening could reduce aneurysm-related deaths among older adults.

Western Australia Screening Trial

The Western Australia trial included 38,480 men who underwent one-time ultrasound screening. Researchers found that smoking was one of the strongest predictors of AAA development. Across the study population, AAA prevalence ranged from 4% to 7.6%, while only 0.3%–0.6% of participants had aneurysms measuring 5 cm or larger, the size often considered for surgical intervention.

Although long-term follow-up showed varying effects on mortality, the study reinforced the importance of identifying aneurysms before rupture, particularly among smokers.

Viborg Trial (Denmark)

The Viborg trial screened thousands of Danish men between 64 and 65 years of age. Researchers observed a significant reduction in deaths related to abdominal aortic aneurysm among individuals invited for screening compared with those who were not screened.

The findings supported nationwide screening programs targeting older men, particularly those with known cardiovascular risk factors.

Chichester Trial (United Kingdom)

The Chichester study examined both men and women to determine whether screening was equally beneficial across sexes.

Researchers found:

• AAA prevalence in women was approximately 1.3%

• Rupture rates remained very low

• AAA-related mortality showed little difference between screened and unscreened women

• Overall mortality rates were similar in both groups

These findings explain why routine AAA screening is generally recommended for men rather than women, except in selected high-risk cases such as women with a strong family history or significant smoking exposure.

What Clinical Trials Reveal About AAA Prevalence

Across multiple international screening studies, most detected aneurysms were relatively small, typically measuring 4–4.5 cm or less. This is important because smaller aneurysms often grow slowly and can be safely monitored through regular imaging rather than immediate surgery.

Clinical evidence consistently demonstrates that screening allows physicians to identify aneurysms before rupture, providing an opportunity for timely surveillance or intervention.

Treatment Options for Abdominal Aortic Aneurysm

Treatment depends primarily on:

• Aneurysm size

• Growth rate

• Presence of symptoms

• Overall patient health

• Risk of rupture

Small aneurysms are usually monitored through periodic imaging, while larger or rapidly expanding aneurysms generally require surgical repair.

Surveillance for Small Aneurysms

Most AAAs measuring less than 5.5 cm in men do not require immediate surgery. Instead, clinicians recommend regular ultrasound or CT imaging to monitor enlargement.

Patients are also encouraged to reduce cardiovascular risk factors by:

• Quitting smoking

• Controlling blood pressure

• Managing cholesterol levels

• Maintaining a healthy weight

• Exercising regularly

• Following prescribed medications

Lifestyle modification can help slow aneurysm progression and improve overall cardiovascular health.

Open Surgical Repair

Open surgical repair involves replacing the weakened section of the aorta with a synthetic graft through an abdominal incision.

Advantages include:

• Excellent long-term durability

• Low risk of future aneurysm-related complications

• Proven effectiveness over several decades

However, recovery is longer because the procedure is more invasive and requires general anesthesia.

Endovascular Aneurysm Repair (EVAR)

Endovascular aneurysm repair (EVAR) is a minimally invasive alternative in which a stent graft is inserted through the femoral arteries and positioned inside the aneurysm.

Potential benefits include:

• Smaller incisions

• Shorter hospital stay

• Faster recovery

• Lower early postoperative complications

Because the graft requires lifelong surveillance, patients undergoing EVAR need regular follow-up imaging to detect possible complications such as endoleaks or graft migration.

Comparing Early Surgery with Active Surveillance

Several major randomized clinical trials have compared early surgical repair with observation for patients who have small AAAs measuring 4.0–5.4 cm.

Researchers evaluated:

• Open surgical repair

• Endovascular aneurysm repair (EVAR)

• Active surveillance with regular imaging

The evidence demonstrated:

• No significant difference in AAA-related mortality between immediate surgery and careful surveillance for small aneurysms.

• Early surgery reduced the risk of aneurysm rupture in selected patients.

• Many patients safely avoided surgery for years through routine monitoring.

These findings support current clinical guidelines recommending surveillance until the aneurysm reaches the size threshold where surgical benefits outweigh procedural risks.

Advances in Personalized AAA Management

Modern research is expanding beyond traditional imaging to improve diagnosis and treatment. Investigators are exploring:

• Genetic susceptibility markers

• Blood-based biomarkers

• Artificial intelligence-assisted imaging analysis

• Personalized risk prediction models

These emerging approaches may help clinicians better identify patients at highest risk for aneurysm growth or rupture, allowing more individualized treatment strategies in the future.

Evidence-Based Clinical Insight

Extensive clinical research demonstrates that abdominal ultrasonography remains the most reliable screening tool for AAA. Large randomized trials consistently show that targeted screening reduces aneurysm-related mortality among high-risk men. Current evidence also supports active surveillance for most small aneurysms, while larger or rapidly expanding AAAs benefit from timely surgical repair. Ongoing advances in imaging, genetics, and biomarker research are expected to further improve early diagnosis and individualized patient care.

Critical Analysis of Recent Research on Abdominal Aortic Aneurysm

Research on abdominal aortic aneurysm (AAA) has advanced significantly over the past decade. Recent studies have focused on improving early diagnosis, refining screening strategies, identifying genetic risk factors, and developing less invasive treatment approaches. Collectively, these findings support the importance of targeted screening while highlighting opportunities to improve patient outcomes through precision medicine and personalized care.

Giant Abdominal Aortic Aneurysms

Buksh et al. (2024) conducted a systematic review combined with a clinical case presentation to examine giant abdominal aortic aneurysms, an uncommon but extremely high-risk form of AAA. The review analyzed a 72-year-old patient alongside 61 previously reported cases.

The authors found that giant AAAs carry a substantially increased risk of rupture because they often remain undetected until reaching a critical size. Their findings reinforce the importance of routine ultrasound screening for high-risk populations, particularly older men with a history of smoking. Detecting aneurysms before they become symptomatic allows physicians to monitor disease progression and intervene before life-threatening complications occur.

This review also highlights the need for increased public awareness and adherence to screening recommendations, as delayed diagnosis remains a significant contributor to preventable mortality.

Advances in Diagnosis and Biomarker Research

Liu (2023) reviewed emerging diagnostic technologies and therapeutic advances for AAA. Beyond traditional imaging techniques, researchers are investigating blood-based biomarkers and molecular pathways involved in aneurysm development.

Promising biomarkers include:

• PPARG

• RAB5C

These biomarkers may eventually help clinicians identify aneurysms earlier, predict disease progression, and personalize treatment decisions.

The editorial also discussed advances in:

• Computed tomography (CT)

• Endovascular treatment

• Drug therapy research

• Animal models used to study aneurysm formation

Although these innovations remain under investigation, they demonstrate how precision medicine may improve future AAA management.

Long-Term Benefits of Screening Programs

An 11-year cohort study by Mansoor et al. (2023) evaluated the effectiveness of a nationwide AAA screening program involving 13,215 men aged 65 years.

The study reported:

• Most aneurysms were detected before rupture.

• Only a small proportion of patients required surgical repair.

• AAA-related deaths remained extremely low throughout follow-up.

• Early detection reduced emergency interventions and improved long-term outcomes.

These findings provide strong evidence that population-based screening programs are effective in reducing aneurysm-related mortality while enabling safer elective treatment when necessary.

Current Challenges and Controversies

Although screening recommendations have proven successful, some researchers argue that existing guidelines may overlook additional high-risk populations.

Zucker and Prabhakar (2018) examined several ongoing controversies, including:

• Underutilization of screening programs

• Cost-effectiveness of expanded screening

• Appropriate screening intervals

• Identification of additional high-risk groups

• Balancing healthcare costs with clinical benefits

The authors suggest that future guidelines should incorporate evolving evidence, including genetic risk profiles and improved risk prediction models, to better identify patients who would benefit from earlier screening.

Future Directions in AAA Research

Modern AAA research is increasingly focused on personalized medicine and preventive care. Advances in genetics, molecular biology, and artificial intelligence are expected to improve both diagnosis and treatment.

Current areas of investigation include:

• Artificial intelligence-assisted ultrasound interpretation

• Machine learning models for rupture prediction

• Blood-based biomarkers for early diagnosis

• Gene-targeted therapies

• Personalized screening based on genetic risk

• Improved endovascular devices

• Medications that may slow aneurysm growth

As these technologies continue to evolve, clinicians may be able to identify high-risk patients earlier and tailor treatment plans more precisely than current practice allows.

Key Takeaways

Abdominal aortic aneurysm remains a major cardiovascular condition because it often progresses without symptoms until rupture occurs. Evidence consistently demonstrates that one-time ultrasound screening for high-risk individuals, particularly men aged 65–75 years who have ever smoked, significantly reduces aneurysm-related mortality.

Research also shows that:

• Ultrasound remains the most accurate and cost-effective screening tool.

• Smoking is the strongest modifiable risk factor.

• Most small aneurysms can be safely monitored with regular imaging.

• Larger or rapidly growing aneurysms usually require surgical repair.

• Advances in genetics, biomarkers, and artificial intelligence may transform future AAA diagnosis and management.

Early detection, appropriate surveillance, and timely intervention remain the foundation of successful AAA prevention and treatment.

Frequently Asked Questions

What is an abdominal aortic aneurysm?

An abdominal aortic aneurysm is a weakening and enlargement of the abdominal portion of the aorta. If the aneurysm ruptures, it can cause severe internal bleeding that requires emergency medical treatment.

Who is at the highest risk of developing an AAA?

Men aged 65 years and older, especially those with a history of smoking, hypertension, high cholesterol, or a family history of AAA, have the highest risk.

What are the symptoms of an abdominal aortic aneurysm?

Most AAAs cause no symptoms. Larger aneurysms may cause abdominal pain, back pain, or a pulsating sensation in the abdomen. A ruptured aneurysm causes sudden severe pain and is a medical emergency.

How is an abdominal aortic aneurysm diagnosed?

Abdominal ultrasound is the preferred screening and diagnostic test because it is highly accurate, non-invasive, and does not expose patients to radiation.

Why is smoking linked to AAA?

Smoking damages blood vessel walls, accelerates atherosclerosis, and weakens the aorta, making aneurysm formation and rupture more likely.

When is surgery recommended for an AAA?

Surgery is generally recommended when an aneurysm reaches approximately 5.5 cm in diameter, grows rapidly, or becomes symptomatic.

What is the difference between open surgery and EVAR?

Open repair replaces the damaged section of the aorta with a synthetic graft through abdominal surgery, whereas endovascular aneurysm repair (EVAR) uses a minimally invasive catheter-based technique to place a stent graft inside the aneurysm.

Can abdominal aortic aneurysms be prevented?

Although not all AAAs can be prevented, quitting smoking, controlling blood pressure, managing cholesterol, maintaining a healthy weight, and attending recommended screening appointments significantly reduce risk.

Is abdominal aortic aneurysm hereditary?

Yes. A family history of AAA increases an individual’s risk, and several genetic variants have been associated with aneurysm development.

Why is ultrasound recommended instead of CT scans for routine screening?

Ultrasound is less expensive, highly accurate, widely available, free of radiation exposure, and suitable for routine population screening.

Evidence-Based Summary

Abdominal aortic aneurysm is a potentially fatal condition that often remains silent until rupture. High-quality evidence supports one-time ultrasound screening for men aged 65–75 years who have ever smoked, as it significantly lowers aneurysm-related mortality. Smoking cessation, cardiovascular risk reduction, and ongoing surveillance for small aneurysms remain essential components of effective AAA management. Emerging research involving biomarkers, genetics, and artificial intelligence is expected to further improve early detection and individualized treatment.

References

Ashton, H., Buxton, M., Day, N., Kim, L., Marteau, T., Scott, R., Thompson, S., & Walker, N. (2002). The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: A randomized controlled trial. The Lancet, 360(9345), 1531–1539. https://doi.org/10.1016/S0140-6736(02)11522-4

Buksh, M. M., Nuzhath, S., Heslop, J., & Moawad, M. (2024). A systematic review and case presentation: Giant abdominal aortic aneurysm. Vascular, 32(3), 521–532. https://doi.org/10.1177/17085381221140166

Guirguis-Blake, J., Beil, T., Senger, C., & Coppola, E. (2019). Primary care screening for abdominal aortic aneurysm: Updated systematic review for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality. https://www.ncbi.nlm.nih.gov/books/NBK551974/

Howard, D. P. J., Banerjee, A., Fairhead, J. F., Handa, A., Silver, L. E., & Rothwell, P. M. (2015). Population-based study of incidence of acute abdominal aortic aneurysms. Journal of the American Heart Association, 4(8). https://doi.org/10.1161/JAHA.115.001926

Lederle, F. A., Wilson, S. E., Johnson, G. R., et al. (2002). Immediate repair compared with surveillance of small abdominal aortic aneurysms. New England Journal of Medicine, 346(19), 1437–1444. https://doi.org/10.1056/NEJMoa012573

Liu, Z. (2023). Editorial: Abdominal aortic aneurysms: Advancements in diagnosis, biomarkers, drug therapeutics, surgical and endovascular treatment. Frontiers in Cardiovascular Medicine, 10. https://doi.org/10.3389/fcvm.2023.1218335

Mansoor, S. M., Rabben, T., Hisdal, J., & Jørgensen, J. J. (2023). Eleven-year outcomes of a screening project for abdominal aortic aneurysm in 65-year-old men. Vascular Health and Risk Management, 19, 459–467. https://doi.org/10.2147/VHRM.S412954

NU505 Unit 2 Assignment: Aortic Abdominal Aneurysm

Roychowdhury, T., Klarin, D., Levin, M. G., et al. (2023). Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target. Nature Genetics, 55(11), 1831–1842. https://doi.org/10.1038/s41588-023-01510-y

Summers, K. L., Kerut, E. K., Sheahan, C., et al. (2019). Prevalence of abdominal aortic aneurysms in the United States: Reevaluating the screening guidelines. Journal of Vascular Surgery, 70(3). https://doi.org/10.1016/j.jvs.2019.06.120

U.S. Preventive Services Task Force. (2019). Screening for abdominal aortic aneurysm: U.S. Preventive Services Task Force recommendation statement. JAMA, 322(22), 2211–2218. https://doi.org/10.1001/jama.2019.18928

Vardulaki, K. A., Walker, N. M., Day, N. E., Duffy, S. W., Ashton, H. A., & Scott, R. A. P. (2000). Quantifying the risks of hypertension, age, sex and smoking in patients with abdominal aortic aneurysm. British Journal of Surgery, 87(2), 195–200. https://doi.org/10.1046/j.1365-2168.2000.01353.x

Zucker, E. J., & Prabhakar, A. M. (2018). Abdominal aortic aneurysm screening: Concepts and controversies. Cardiovascular Diagnosis and Therapy, 8(Suppl. 1), S108–S117. https://doi.org/10.21037/cdt.2017.09.13